Literature DB >> 15115915

Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis.

Cyril Flamant1, Alexandra Henrion-Caude, Pierre-Yves Boëlle, François Brémont, Jacques Brouard, Bertrand Delaisi, Jean-François Duhamel, Christophe Marguet, Michel Roussey, Marie-Claude Miesch, Michèle Boulé, Richard C Strange, Annick Clement.   

Abstract

OBJECTIVES: Progression and severity of lung disease differs markedly and early between patients with cystic fibrosis (CF). We investigated the hypothesis that polymorphisms in the detoxifying enzymes glutathione-S-transferase (GST) could influence phenotypic presentation of lung disease in CF.
METHODS: Genotypes for GSTM1, GSTM3, GSTP1 and GSTT1 were determined in a cohort of 146 children with CF by PCR-based methods. Pulmonary function, assessed by spirometric measures of forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), was analysed in children at the age of 9.
RESULTS: No association between spirometric measurements, and GSTM1, GSTP1 or GSTT1 genotypes was found. As compared with patients homozygous for GSTM3*A allele, CF children carrying the GSTM3*B allele displayed a significant better lung function, assessed by both mean values of FEV1 and of FVC (respectively P = 0.01 and P = 0.002). These correlations remained significant after adjustment for potential confounding factors (respectively adjusted P = 0.008 and P = 0.002) and also in subgroups of CF patients who carry the deltaF508 CFTR mutation. Haplotype analysis of GSTM3 in combination with GSTM1 indicated that the positive impact of GSTM3*B allele on pulmonary performances was barely influenced by the GSTM1 genotypes of CF children.
CONCLUSIONS: These data provide the first evidence suggesting that polymorphism of the GSTM3 gene contributes to clinical severity in CF, which may have prognostic significance and could prompt to start a more targeted therapy in young patients with CF. Copyright 2004 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115915     DOI: 10.1097/00008571-200405000-00004

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  16 in total

Review 1.  The gallbladder and biliary tract in cystic fibrosis.

Authors:  Michael P Curry; John E Hegarty
Journal:  Curr Gastroenterol Rep       Date:  2005-05

2.  Alterations in gene expression and DNA methylation during murine and human lung alveolar septation.

Authors:  Alain Cuna; Brian Halloran; Ona Faye-Petersen; David Kelly; David K Crossman; Xiangqin Cui; Kusum Pandit; Naftali Kaminski; Soumyaroop Bhattacharya; Ausaf Ahmad; Thomas J Mariani; Namasivayam Ambalavanan
Journal:  Am J Respir Cell Mol Biol       Date:  2015-07       Impact factor: 6.914

Review 3.  Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?

Authors:  Rainer Büscher; Hartmut Grasemann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-11       Impact factor: 3.000

4.  Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity.

Authors:  Alekh Paranjapye; Manon Ruffin; Ann Harris; Harriet Corvol
Journal:  J Cyst Fibros       Date:  2019-11-14       Impact factor: 5.482

5.  Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease.

Authors:  Edward F McKone; Jing Shao; Daisy D Frangolias; Cassie L Keener; Cynthia A Shephard; Federico M Farin; Mark R Tonelli; Peter D Pare; Andrew J Sandford; Moira L Aitken; Terrance J Kavanagh
Journal:  Am J Respir Crit Care Med       Date:  2006-05-11       Impact factor: 21.405

Review 6.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

7.  Variation in the GST mu locus and tobacco smoke exposure as determinants of childhood lung function.

Authors:  Carrie V Breton; Hita Vora; Muhammad T Salam; Talat Islam; Made Wenten; W James Gauderman; David Van den Berg; Kiros Berhane; John M Peters; Frank D Gilliland
Journal:  Am J Respir Crit Care Med       Date:  2009-01-16       Impact factor: 21.405

8.  Genome-wide association study of lung function decline in adults with and without asthma.

Authors:  Medea Imboden; Emmanuelle Bouzigon; Ivan Curjuric; Adaikalavan Ramasamy; Ashish Kumar; Dana B Hancock; Jemma B Wilk; Judith M Vonk; Gian A Thun; Valerie Siroux; Rachel Nadif; Florent Monier; Juan R Gonzalez; Matthias Wjst; Joachim Heinrich; Laura R Loehr; Nora Franceschini; Kari E North; Janine Altmüller; Gerard H Koppelman; Stefano Guerra; Florian Kronenberg; Mark Lathrop; Miriam F Moffatt; George T O'Connor; David P Strachan; Dirkje S Postma; Stephanie J London; Christian Schindler; Manolis Kogevinas; Francine Kauffmann; Debbie L Jarvis; Florence Demenais; Nicole M Probst-Hensch
Journal:  J Allergy Clin Immunol       Date:  2012-03-16       Impact factor: 10.793

9.  Frequencies of glutathione s-transferase (GSTM1, GSTM3 AND GSTT1) polymorphisms in a Malaysian population.

Authors:  Mustafa A Alshagga; Norazlina Mohamed; Ahmad Nazrun Suhid; Ibrahim Abdel Aziz Ibrahim; Syed Zulkifli Syed Zakaria
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

10.  Genetic influences on cystic fibrosis lung disease severity.

Authors:  Colleen A Weiler; Mitchell L Drumm
Journal:  Front Pharmacol       Date:  2013-04-23       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.